Navigation Links
Paloma Pharmaceuticals Presents at the Association for Research in Vision and Ophthalmology 2009 Meeting
Date:5/6/2009

- Presentation describes Palomid 529 as a first-in-class Dual TORC1/TORC2 complex inhibitor of the PI3K/Akt/mTOR pathway showing efficacy in retinal scarring caused by retinal detachment -

JAMAICA PLAIN, Mass., May 6 /PRNewswire/ -- Paloma Pharmaceuticals, Inc. presented "Palomid 529, An Inhibitor of the Akt/mTOR Pathway Reduces Photoreceptor Cell Death Following Experimental Retinal Detachment", today at the annual meeting of the Association for Research in Vision and Ophthalmology 2009 (ARVO 2009), This study, presented by Geoffrey P. Lewis, Ph.D. (along with G. Luna, J. Byun, E.A. Chapin and S.K. Fisher) of the Neuroscience Research Institute and Molecular Cell & Developmental Biology Department of the University of California, Santa Barbara, CA. has been accepted for publication in the journal Investigative Ophthalmology and Visual Science.

Work from this study indicates that intravitreally administered Palomid 529 slows photoreceptor cell death following retinal detachment in a seven day rabbit study without obvious side effects to the retina. This suggests that inhibiting the PI3K/Akt/mTor signal transduction pathway by Palomid 529 may be neuroprotective to photoreceptors and perhaps represents a novel therapy for other retinal diseases such as proliferative vitreoretinopathy, macular degeneration and diabetic retinopathy. "We are excited over the results of this study in that it further adds to our data showing the versatility of Palomid 529 for diseases of retinal and subretinal origin. Furthermore, results from a separate six month intravitreal ocular biodistribution study, shows the presence of Palomid 529 in the eye for at least six months. This observation coupled with efficacy data described here and in earlier studies indicates that Palomid 529 may be administered infrequently, possibly as little as once a year," says David Sherris, Ph.D., President and CEO of Paloma Pharmaceuticals.


'/>"/>
SOURCE Paloma Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Poniard Pharmaceuticals Reports First Quarter 2009 Financial Results and Provides a Corporate Update
2. Transcept Pharmaceuticals to Report First Quarter 2009 Results
3. Oramed Pharmaceuticals Announces Launch of Phase 2B Clinical Trials in South Africa of its Oral Insulin Capsule
4. Potentia Pharmaceuticals POT-4 Drug Candidate for Age-Related Macular Degeneration Successfully Completes Phase I Clinical Trial - Prepares for Phase II
5. Poniard Pharmaceuticals to Present New Data from Phase 2 Clinical Trials of Picoplatin in Multiple Tumor Types at the 45th Annual Meeting of the American Society of Clinical Oncology
6. Peregrine Pharmaceuticals Completes Patient Enrollment in its Phase II Trial of Bavituximab Plus Docetaxel in Breast Cancer Patients
7. Raptor Pharmaceuticals Receives Notices of Allowance for Two NeuroTrans(TM) Patent Applications
8. Merz Pharmaceuticals Announces Results of Three Clinical Trials With NT-201 (Botulinum Neurotoxin Type A Free From Complexing Proteins) in Movement Disorder Patients
9. Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 First Quarter Results
10. Affitech-Discovered Anti-PS Antibodies in Development by Peregrine Pharmaceuticals Show Excellent Functionality in Preclinical Studies
11. Ferring Pharmaceuticals Launches Phase IIIB Trial of Degarelix as Intermittent Therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014  Valeant Pharmaceuticals International, Inc. ... that the applicable waiting period under the Hart-Scott-Rodino Antitrust ... previously announced tender offer by its indirect wholly-owned subsidiary, ... shares of common stock of Solta Medical, Inc. (NASDAQ: ...
(Date:1/15/2014)... Ohio , Jan. 15, 2014  A novel wearable injector ... easy and painless for patients to self-inject prescription drugs in ... disorders, including cancer, blood diseases, autoimmune deficiencies, and genetic disorders.  ... to grow to $220B by 2018, according to analysts.   Many ...
(Date:1/14/2014)... , Jan. 14, 2014 The Brandeis Medical Center, led ... a premier and affordable laser tattoo removal experience with ... Brandeis, focus is in providing high quality cosmetic services with cutting ... " Southern California has seen a ...
Breaking Medicine Technology:Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2Beverly Hills Physician Features Tattoo Removal with the Astanza Duality Laser, Offers $99 Special 2
... 29 Asahi Kasei Medical Co., Ltd. is pleased to ... MF-SL, its new range of microfilters for bioprocessing applications. Designed specifically ... biopharmaceutical manufacturers to improve the efficiency and effectiveness of their protein ... , ...
... IRIDEX Corporation (Nasdaq: IRIX ) today announced that it will release its ... August 5, 2010 .  In conjunction with the release, the Company will ... Eastern Time on Thursday, August 5, 2010 ... , , ...
Cached Medicine Technology:Launch of BioOptimalâ„¢ MF-SL Microfilters for Bioprocessing 2IRIDEX Announces Second Quarter 2010 Conference Call and Release Date 2
(Date:4/18/2014)... University School of Medicine researchers have been awarded two-year ... Novo Nordisk announced this month. Of the 110 initial ... Biologics Science Forum Program, only four projects were funded, ... They are Jonathan Powell, M.D., Ph.D.; G. William Wong, ... Powell, a professor of oncology, will use his $500,000 ...
(Date:4/18/2014)... April 18, 2014) Benaroya Research Institute at Virginia ... blocking a particular molecule in metastatic breast cancer reduces ... of lung metastases. BRI scientists have found in models ... tumors by 60 - 80 percent and can keep ... The $1.8 million five-year grant comes from the National ...
(Date:4/18/2014)... 18, 2014) ― A new study in the ... in health-related Google searches reveals a recurring pattern that ... , Investigators from San Diego State University, the ... Campaigns, analyzed "healthy" Google searches (searches that included the ... originating in the U.S. from 2005 to 2012. They ...
(Date:4/18/2014)... could lead to potential new treatments for breaking the ... , Fibrosis, or scarring, is a hallmark of the ... can lead to serious organ damage and, in some ... centers on findings made by Swati Bhattacharyya, PhD, research ... a specific protein plays in promoting fibrosis. , ...
(Date:4/17/2014)... in non-cancerous prostate tissue may have nearly twice the ... no inflammation, according to results of a new study ... Center. , The link between persistent inflammation and cancer ... cancer those with a Gleason score between 7 ... aggressive and rapidly growing prostate cancers. , "What we,ve ...
Breaking Medicine News(10 mins):Health News:Benaroya Research Institute evaluates immunology approach to blocking breast cancer 2Health News:New research shows people are thinking about their health early in the week 2Health News:New clues on tissue scarring in scleroderma 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 3
... bog outshines 19 commonly eaten fruits for the ... latest,Agricultural Research Service Report from USDA, containing the ... foods, shows cranberries,score among the highest of all ... The report includes antioxidant values for a ...
... Children with autism have normal-size heads at birth but ... of age, a period that precedes the onset of ... disorder, according to new research from the University of ... aberrant growth is present in children who have the ...
... Conn.A protein has been found that influences the response of ... such as occurs during a heart attack, a team of ... This finding may present a new therapeutic approach to treating ... The protein, macrophage migration inhibitory factor (MIF), was found to ...
... Bay Park to be the focus of this inaugural ... ... An unclimbed mountain near Mount Abbe,in the northern reaches of Alaska,s ... Expedition for Cancer Research, a quest,sponsored by Fred Hutchinson Cancer Research ...
... 30 Prime Therapeutics (Prime) has,joined the Center ... from,the pharmacy benefit manager (PBM) industry. The Center ... collaborates with leading,organizations to develop and promote innovative ... the health of employees. Members,of the Center represent ...
... estrogen 55 times faster , , WEDNESDAY, Jan. 30 (HealthDay ... release a potentially harmful chemical 55 times faster than ... found in the plastics that make up water bottles, ... acts as an environmental estrogen and can disrupt the ...
Cached Medicine News:Health News:Cranberries' Antioxidant Level Tops List in USDA Report 2Health News:Cranberries' Antioxidant Level Tops List in USDA Report 3Health News:Accelerated head growth can predict autism before behavioral symptoms start 2Health News:Hutchinson Center Announces First Unclimbed Mountain to be Tackled by Big Expedition for Cancer Research 2Health News:Prime Therapeutics Becomes First PBM to Join the Center for Health Value Innovation 2Health News:Heating Plastic Bottles Releases Potentially Harmful Chemical 2Health News:Heating Plastic Bottles Releases Potentially Harmful Chemical 3
... is an automated, multiparametric immunoassay ... device stores the calibration in ... the cost-per-patient result. Plus, with ... ease of use and uni/bi-directional ...
Alpha prime immunoassay system features unsurpassed quality of results, full automation of EIA tests for microplate applications, complete walk-away, up to 18 different assays per run, photometric an...
... Vitros 250 is a flexible ... in multiple environments small ... clinics and satellite locations. The ... dilution, and can be automated ...
AxSYM Plus provides cutting-edge ergonomics and smart new features that mean increased ease-of-use and enhanced reliability. Also, advanced software means less operator intervention and high-integrit...
Medicine Products: